Pharmacogenomics in Cardiovascular Therapeutics

Intro to PGx in CVD - Gene-Drug Dance

• Pharmacogenomics (PGx): Study of how an individual's genetic makeup influences their response to drugs.
• CVD Context: Tailors cardiovascular drug choice and dosage based on a patient's unique genetic profile.
• "Gene-Drug Dance": Describes the critical interplay between genes (e.g., CYP2C9, VKORC1) and cardiovascular drugs.
• Primary Goals:
  • Maximize drug efficacy.
  • Minimize adverse drug reactions (ADRs).
  • Achieve personalized pharmacotherapy for conditions like thrombosis or hyperlipidemia.

⭐ Key example: CYP2C19 gene variants significantly impact clopidogrel's antiplatelet effect, necessitating dose adjustments or alternative therapies for optimal patient outcomes in cardiovascular disease management, particularly post-percutaneous coronary intervention (PCI).

Warfarin & Clopidogrel - Clot Busters' Code

• Warfarin:
  • Narrow therapeutic index anticoagulant.
  • Key genes: VKORC1 (target), CYP2C9 (metabolism).
  • VKORC1 variants (e.g., -1639G>A): ↑ sensitivity → require ↓ warfarin dose.
  • CYP2C92, CYP2C93 alleles: ↓ metabolism → ↑ bleeding risk → require ↓ warfarin dose.
  • Genotyping helps predict initial dose, reducing ADRs.
• Clopidogrel:
  • Prodrug, activated by CYP2C19.
  • CYP2C19 loss-of-function (LOF) alleles (e.g., *2, *3): ↓ platelet inhibition → ↑ risk of MACE, esp. post-PCI stent thrombosis.
  • Alternatives for LOF carriers (poor metabolizers): Prasugrel, Ticagrelor.

⭐ CYP2C19 LOF alleles in PCI patients: consider alternative antiplatelets (prasugrel, ticagrelor) due to ↑ MACE risk with clopidogrel.

Statins & Beta-Blockers - Heart Helpers' Helix

• Statins
  • SLCO1B1 (OATP1B1 transporter):
    • c.521T>C variant: ↓ liver uptake → ↑ plasma statin → ↑ myopathy risk (esp. simvastatin 40mg).
    • Action: Test; consider lower dose/alternative.
  • ABCG2 (BCRP): Variants → ↑ rosuvastatin levels.

  ⭐ SLCO1B1 variants are major predictors of statin-induced myopathy.

• Beta-Blockers
  • CYP2D6 (metabolism):
    • Metabolizes metoprolol, carvedilol.
    • Poor Metabolizers (PMs): ↑ drug levels → ↑ bradycardia/hypotension risk.
    • Ultrarapid Metabolizers (UMs): ↓ drug levels → ↓ efficacy.
    • Action: Dose adjustment/alternative.
  • ADRB1 (β1-receptor):
    • Variants (Ser49Gly, Arg389Gly) may alter BP/HR response. Arg389Gly linked to better response. 📌 Mnemonic: Beta-blockers Dance (CYP2D6) with Receptors (ADRB1).

Other PGx Targets & Guidelines - Cardio Code Crackers

• Beta-blockers:
  • ADRB1 (e.g., Arg389Gly polymorphism): Influences response to drugs like metoprolol.
  • CYP2D6: Critical for metoprolol, carvedilol metabolism. Poor metabolizers (PMs) face ↑ risk of bradycardia, hypotension.
• Nitrates (e.g., Glyceryl Trinitrate - GTN):
  • ALDH2 deficiency (e.g., ALDH2*2 allele): Leads to ↓ efficacy due to impaired bioactivation. Common in East Asian populations.
• Antiarrhythmics:
  • Channelopathy genes (SCN5A, KCNH2, KCNE1): Variants predispose to drug-induced Long QT Syndrome (diLQTS).
• Diuretics (Thiazides):
  • ADD1 (alpha-adducin, Gly460Trp): May predict blood pressure response.
• Clinical Guidelines & Implementation:
  • CPIC (Clinical Pharmacogenetics Implementation Consortium) & DPWG (Dutch Pharmacogenetics Working Group): Provide key evidence-based, actionable guidelines for gene-drug pairs.
  • Challenges: Cost, turnaround time, electronic health record (EHR) integration, clinician education.

⭐ The ALDH2*2 allele, prevalent in approximately 30-50% of East Asian individuals, significantly impairs the bioactivation of nitroglycerin, thereby reducing its vasodilatory efficacy and potentially leading to treatment failure in angina pectoris patients carrying this variant.

High‑Yield Points - ⚡ Biggest Takeaways

• Warfarin dosing: VKORC1 & CYP2C9 variants guide therapy to balance efficacy and bleeding.
• Clopidogrel: CYP2C19 loss-of-function alleles reduce activation, ↑ risk of stent thrombosis.
• Statins: SLCO1B1 variants (e.g., for simvastatin) ↑ risk of myopathy.
• Beta-blockers: CYP2D6 polymorphisms (e.g., metoprolol) alter metabolism and response.
• ACE inhibitors: ACE I/D polymorphism may influence response and cough incidence.
• Nitrates: ALDH2 deficiency can lead to reduced efficacy in angina treatment.